TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01214226
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg prolonged-released tablets 3 time per day for 1 month.
Study: NCT00860223
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00860223
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HKI-272
Study: NCT04154033
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical naltrexone cream (1%)
Study: NCT01233505
Drug: veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01233505
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02461771
Drug: Pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.
Study: NCT02808065
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered dose were individualized according to their own prescription
Study: NCT02808065
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered dose were individualized according to their own prescription
Study: NCT00854308
Drug: Erlotinib HCl
Normalized name: erlotinib HCl
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg oral dose once daily.
Study: NCT00211848
Drug: Pegylated Interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00211848
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00854308
Drug: MetMAb
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
Study: NCT00854308
Drug: placebo (0.9 % saline)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Intravenous infusion every 3 weeks.
Study: NCT06309732
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6mg at each cycle
Study: NCT06309732
Drug: Dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/m2
Study: NCT06309732
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90mg/m2 injection for infusion
Study: NCT06309732
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m2
Study: NCT06309732
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 37.5mg/m2
Study: NCT01221792
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day).
Study: NCT00431769
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
Study: NCT01864655
Drug: saracatinib
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral drug given to experimental group
Study: NCT04121975
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
Study: NCT04121975
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
Study: NCT03775629
Drug: Polmacoxib and Tramadol combination
Normalized name: tramadol and celecoxib
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride , Polmacoxib
Study: NCT03775629
Drug: Polmacoxib
Normalized name: polmacoxib
DrugBank: Polmacoxib (DB12399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polmacoxib
Study: NCT03775629
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride (HCl)
Study: NCT01390844
Drug: Boceprevir (BOC)
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg capsules, 800 mg three times daily by mouth
Study: NCT01390844
Drug: Placebo to boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg placebo capsules, 800 mg three times daily by mouth
Study: NCT01390844
Drug: Peginterferon alfa-2b (PEG)
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mcg/kg/week subcutaneously
Study: NCT01390844
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
Study: NCT01390844
Drug: Cross-Over Boceprevir Treatment
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
Study: NCT01316445
Drug: nasal Midazolam
Normalized name: midazolam Nasal Spray
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
Study: NCT00167739
Drug: Quinine plus sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00229593
Drug: Nestorone gel
Normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
Study: NCT00378690
Drug: leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LHRH antagonist
Study: NCT02324803
Drug: pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: continuous treatment of 800 mg pazopanib once daily until disease progression
Study: NCT05123170
Drug: Dexmedetomidine Injectable Solution [Dexdomitor]
Normalized name: dexmedetomidine Injectable Solution [Dexdomitor]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
Study: NCT05123170
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous regional anaesthesia
Study: NCT00025363
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00025363
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00025363
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00025363
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00025363
Drug: tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01186406
Drug: Gliadel
Normalized name: Gliadel
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
Study: NCT00334958
Drug: Rufinamide
Normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
Study: NCT02187497
Drug: Low dose of BIBR 277
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02187497
Drug: Medium dose of BIBR 277
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02187497
Drug: High dose of BIBR 277
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04397601
Drug: Folfiri/Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
Study: NCT04397601
Drug: Folfiri/Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
Study: NCT00105417
Drug: IL-7
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03773263
Drug: traditional IVM system
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
Study: NCT01086085
Drug: Adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 10 mg po once daily for 36 weeks
Study: NCT01186406
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days.
Study: NCT01086085
Drug: peginterferon alfa-2a [PEGASYS]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Study: NCT01086085
Drug: peginterferon alfa-2a [PEGASYS]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Study: NCT01086085
Drug: peginterferon alfa-2a [PEGASYS]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
Study: NCT03988088
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT03048500
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00169026
Drug: Clozapine versus typical (conventional) and atypical antipsychotic medications
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04350580
Drug: Human immunoglobulin
Normalized name: Human immunoglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human immunoglobulin 2g/kg over 4 days (0.5g/kg/d)
Study: NCT00957151
Drug: Creon
Normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01186406
Drug: Temodar
Normalized name: Temodar
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
Study: NCT03716427
Drug: tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
Study: NCT03716427
Drug: dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
Study: NCT05675176
Drug: BCG
Normalized name: BCG
DrugBank: Bacillus calmette-guerin substrain danish 1331 live antigen (DB12386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Instillation
Study: NCT00048126
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
Study: NCT00014105
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00014105
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01193595
Drug: Ombrabulin (AVE8062)
Normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT01193595
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT00167648
Drug: Leuprolide or goserelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
Study: NCT01061411
Drug: Dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT01061411
Drug: Sunitinib Malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00124228
Drug: Human Albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
Study: NCT00807170
Drug: ZD6474 (Vandetanib)
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg as a once daily oral dose, 21 days
Study: NCT01449539
Drug: Hyperbaric Oxygen Therapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
Study: NCT00376337
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT00471900
Drug: dehydroepiandrosterone (DHEA)
Normalized name: DEHYDROEPIANDROSTERONE (DHEA) CAP/TAB
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03716427
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
Study: NCT03716427
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
Study: NCT02098720
Drug: Conbercept
Normalized name: Conbercept
DrugBank: Conbercept (DB12460)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03437564
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vortioxetine tablet
Study: NCT00151983
Drug: Methylphenidate Transdermal System
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
Study: NCT03574857
Drug: Metolazone Oral Tablet
Normalized name: metolazone Oral Tablet
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
Study: NCT00916149
Drug: levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
Study: NCT02079766
Drug: Flortaucipir F18
Normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 370 megabecquerel (MBq) IV single-dose
Study: NCT00916149
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study.
Study: NCT01665547
Drug: l-carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3gm l-carnitine from day 1 to day 12 of the menstrual cycle
Study: NCT00113022
Drug: Org 24448
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
Study: NCT02101021
Drug: Momelotinib
Normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (s) administered orally once or twice daily
Study: NCT02101021
Drug: Placebo to match momelotinib
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match momelotinib tablets administered orally once or twice daily
Study: NCT02101021
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study: NCT02101021
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study: NCT05016206
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan tablets administered as a single oral dose.
Study: NCT05016206
Drug: Moxifloxacin-matching Placebo
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin-matching placebo was administered as a single oral dose.
Study: NCT05016206
Drug: Danicopan-matching placebo
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan-matching placebo was administered as a single oral dose.
Study: NCT05016206
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg was administered as a single tablet oral dose.
Study: NCT02632721
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632721
Drug: BI 836858
Normalized name: anti-Cd33 monoclonal antibody BI 836858
DrugBank: BI-836858 (DB17267)
Approvals — FDA: no, EMA: no, PMDA: no